gastric cancer
Conditions
Interventions
Experimental group:Three hole laparoscopic surgery
Control group:Five hole laparoscopic surgery
Sponsors
The First Affiliated Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The operator can complete radical D2 lymph node dissection (the number of lymph nodes checked must reach at least 15 to ensure the quality of the operation); 2. Physical condition and visceral function allow for major abdominal surgery; 3. Willing to and able to abide by the protocol during the study period, provide written informed consent before entering the study screening, and the patient has understood that he can withdraw from the study at any time without any loss; 4. Aged 18-75 years old, gastric adenocarcinoma confirmed by preoperative pathology and the tumor is located in the middle and lower part of the gastric body, laparoscopic D2 distal gastrectomy is planned; 5. Expected survival time > 6 months, without other serious concomitant diseases and with good organ function; 6. BMI 60; ECOG score: 0-2; 16. Postoperative patients can receive chemotherapy according to CSCO guidelines.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women, who are in the childbearing period and have not taken effective contraceptive measures; 2. Combining serious medical diseases or conditions: such as clinically serious (ie, active) heart disease, serious, uncontrolled medical diseases and infections, severe uncontrolled digestive disorders, severe electrolyte disorders, active dissemination intravascular coagulation, major organ failure, such as decompensated heart, lung, liver, kidney failure, symptoms of peripheral neuropathy, etc., can not tolerate D2 radical gastrectomy; 3. Organ transplantation requires immunosuppressive therapy; 4. Severe uncontrolled recurrent infection, or other serious uncontrolled accompanying diseases; 5. History of other malignant tumors within 5 years after the start of the trial, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 6. Patients without self-awareness and mental disorders; 7. Have a history of organ transplantation (including bone marrow autologous transplantation and peripheral stem cell transplantation); 8. Taking other experimental drugs at the same time or being in other clinical trials; 9. Those who have received biological therapy or other anti-cancer traditional Chinese medicine with an interval of less than 4 weeks; 10. During the operation, the surgeon thinks that the three-hole total laparoscopic radical gastrectomy for distal gastrectomy cannot be completed or other surgical methods need to be changed; 11. Cannot receive chemotherapy after surgery; 12. The general type of tumor is Borrmann type IV; 13. Tumor recurrently invades surrounding organs (T4b) or combined with distant metastasis; 14. Combined organ resection is required during the operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free surviva;Operation time; | — |
Countries
China
Contacts
Public ContactJi Gang
The First Affiliated Hospital of Air Force Military Medical University
Outcome results
None listed